Background Among patients with
atrial fibrillation and stable
coronary artery disease, those with histories of atherothrombotic disease are at high-risk for future ischemic events. This study investigated the efficacy and safety of
rivaroxaban monotherapy in patients with
atrial fibrillation,
coronary artery disease, and histories of atherothrombotic disease. Methods and Results This was a post hoc subanalysis of the AFIRE (
Atrial Fibrillation and Ischemic Events With
Rivaroxaban in Patients With Stable
Coronary Artery Disease) trial. Patients with non-valvular
atrial fibrillation and
coronary artery disease were recruited and randomized to receive the
rivaroxaban monotherapy or combination
therapy with
rivaroxaban plus
antiplatelet drug. For the purpose of this sub-study, participants were divided into 2 subgroups, including the
atherothrombosis group (those with histories of
myocardial infarction,
stroke, and/or
peripheral artery disease; n=1052, 47.5%) and non-
atherothrombosis group (n=1163, 52.5%). The efficacy end point included cardiovascular events or all-cause death, while the safety end point was major
bleeding. Net adverse events consisted of all-cause death,
myocardial infarction,
stroke, or major
bleeding. In the
atherothrombosis group,
rivaroxaban monotherapy was significantly associated with a lower risk of net adverse events when compared with combination
therapy (hazard ratio [HR], 0.50; 95% CI, 0.34-0.74; P<0.001), with a decrease in both efficacy (HR, 0.68; 95% CI, 0.47-0.99; P=0.044) and safety (HR, 0.37; 95% CI, 0.19-0.71; P=0.003) end points. By contrast, there were no differences between treatment outcomes for the non-
atherothrombosis group. Conclusions
Rivaroxaban monotherapy significantly reduced net adverse events as compared with combination
therapy for patients with
atrial fibrillation,
coronary artery disease, and prior atherothrombotic disease. Registration URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000016612. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02642419.